Devonian Health Group Inc, a clinical stage botanical pharmaceutical corporation focused on developing a unique portfolio of botanical prescription drugs and cosmeceutical products, recently provided an update on its phase 2 clinical trial in adult patients suffering from atopic dermatitis.
The phase 2 clinical trial of Thykamin in adult patients with Mild-to-Moderate Atopic Dermatitis is progressing as planned. In order to accelerate the recruitment of patients, Devonian is expanding the number of sites from 6 to 12 clinics across Canada. The study should be completed later this year, according to a news release.
Devonian also announces that its Cosmeceutical R&D initiative is progressing as expected. Devonian’s Cosmeceutical R&D program is focused on external Exposome associated with skin aging namely sun radiation (UVA/UVB, Infrared A and Blue Light), Blue light radiation from other sources than sun and pollution.
Blue light emission, which is also called high-energy visible light (HEV), stems from the sun and also from digital screens of computers, smartphones, televisions, tablets and from LED lamps. The negative impact of Blue light on ocular health and on circadian system ( sleep pattern) has been reported in several scientific manuscripts. There is also evidence that it has adverse effects on different dermal cells, that it generates Reactive Oxygen Species (oxidants) and is inducing skin aging.
Devonian has completed the formulation of a new Blue light photoprotection product. The product has been developed as a day cream with, as one of the main ingredients, Devonian’s patented R-Spinasome. The product will be tested in human during 2019 and is expected to be ready for commercialisation in 2020, the release continues.
“This is the first product emerging from our Cosmeceutical R&D program focused on Exposome. Blue light is around us all the time, and consumers are now aware of the increased risks of daily exposition to this radiation. We are therefore developing this new product in order to offer consumers an effective product with protective attributes against the negative impacts of Blue light may have on their skin.
“As all our products, the efficacy and safety of our Blue light protection cream will be assessed through a double-blind, placebo controlled clinical study. Our team is currently selecting skin biomarkers to be included in this study which should be completed by year-end.” says Devonian’s resident & CEO, Dr Andre P. Boulet, in the release.
[Source(s): Devonian Health Group Inc, Business Wire]